{'fraction_non_alphanumeric': 0.015659955257270694, 'fraction_numerical': 0.008948545861297539, 'mean_word_length': 5.532846715328467, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expanding the phenotypic spectrum of CYP1B1 associated primary congenital glaucoma

doxycycline at 41%, with a success rate of 55% for patients on only doxycycline, and a success rate of 39% for patients on doxycycline and corticosteroid. Moreover, we observed that patients who had more frequent symptoms were more likely to fail doxycycline and topical corticosteroid therapy, and require other surgical alternatives. Limitations of our study include its retrospective nature and selection bias from patients lost to follow up. In conclusion, the treatment of RCES with oral doxycycline in our series had a much lower efficacy than what is reported in the current literature. Given that there are side effects associated with doxycycline and topical corticosteroids, clinicians may wish to consider initiating discussions on more aggressive interventional modalities to reduce disease burden.